Search

Axsome Therapeutics Inc

Cerrado

SectorSanidad

207.46 0.81

Resumen

Variación precio

24h

Actual

Mínimo

200.92

Máximo

210.12

Métricas clave

By Trading Economics

Ingresos

13M

-51M

Ventas

27M

218M

BPA

-0.99

Margen de beneficios

-23.498

Empleados

1,346

EBITDA

11M

-50M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+40.8% upside

Dividendos

By Acuity

Próximas Ganancias

2 nov 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-34M

11B

Apertura anterior

206.65

Cierre anterior

207.46

Noticias sobre sentimiento de mercado

By Acuity

49%

51%

131 / 339 Clasificación en Healthcare

Axsome Therapeutics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

8 sept 2026, 19:36 UTC

Axsome Therapeutics Inc shares are higher today amid routine trading, with no specific company news identified. The stock has gained since Friday's close.

4 sept 2026, 22:40 UTC

Axsome Therapeutics Inc. shares are higher in after-market hours, recovering from an earlier pullback and achieving a notable return since Friday's close.

3 sept 2026, 20:07 UTC

Axsome Therapeutics Inc shares are trading lower today, with no specific news identified to explain the decline amid a broader market downturn.

2 sept 2026, 20:01 UTC

News

Axsome Therapeutics will participate in several upcoming investor conferences, boosting shares amid positive sentiment regarding its outreach efforts.

1 sept 2026, 19:51 UTC

Event
News

Axsome Therapeutics Inc. announced the first patient has been dosed in the SUMMIT Phase 3 trial of AXS-05 for smoking cessation, boosting shares higher.

31 ago 2026, 21:02 UTC

Event

Axsome Therapeutics shares rise in after-market hours following the dosing of the first patient in the SUMMIT Phase 3 trial for AXS-05.

29 ago 2026, 00:01 UTC

Axsome Therapeutics Inc is higher in after-market trading, advancing since Friday's close, though still below its 20-day moving average.

28 ago 2026, 23:46 UTC

Axsome Therapeutics Inc shares are higher in after-market hours, though no specific news was identified to explain the movement. They remain below their 20-day moving average.

27 ago 2026, 19:36 UTC

Axsome Therapeutics Inc. shares are trading lower, continuing a decline since Wednesday and remaining near the lower end of their one-month trading range.

26 ago 2026, 19:36 UTC

Axsome Therapeutics Inc. shares are trading higher today, recovering from an early dip. The stock remains below its 20-day moving average.

25 ago 2026, 21:01 UTC

Axsome Therapeutics Inc shares are lower in after-market hours, continuing a trend of four consecutive sessions finishing down and trading below the 20-day moving average.

24 ago 2026, 21:01 UTC

Axsome Therapeutics Inc shares are lower in after-market trading. The stock has declined for four consecutive sessions and remains below its 20-day moving average.

21 ago 2026, 19:41 UTC

Axsome Therapeutics Inc. shares are lower today, retracing from earlier gains and remaining below the 20-day moving average amid rising Treasury yields.

20 ago 2026, 20:01 UTC

Axsome Therapeutics Inc's shares are declining amid broader market pressures from Walmart's disappointing earnings, raising concerns about consumer spending.

17 ago 2026, 19:16 UTC

Axsome Therapeutics Inc shares are higher today, continuing an upward trend since Friday's close. No specific news was identified to explain the movement.

14 ago 2026, 19:36 UTC

Axsome Therapeutics Inc shares are higher today, rebounding from an earlier pullback, despite a broader market influenced by a decline in retail sales.

13 ago 2026, 19:56 UTC

Axsome Therapeutics Inc shares are declining, retracing from earlier session highs amid broader market trends and rising U.S. unemployment claims.

12 ago 2026, 22:36 UTC

Axsome Therapeutics shares higher in after-market trading, with no specific news identified. Broader market stability follows recent inflation data easing rate hike concerns.

11 ago 2026, 19:45 UTC

Social Media
News

Axsome Therapeutics shares are lower following a second-quarter loss of 99 cents per share, missing the consensus estimate of 83 cents.

10 ago 2026, 23:06 UTC

Axsome Therapeutics Inc shares are lower during after-market hours amid mixed market sentiment. The stock is trading below its 20-day moving average.

7 ago 2026, 19:52 UTC

Axsome Therapeutics Inc shares are higher during Friday's session, recovering from a brief dip after reaching a session high. No specific news was identified.

6 ago 2026, 23:01 UTC

Axsome Therapeutics Inc. is trading higher in after-market hours, showing stability despite no specific news. The stock remains below its 20-day moving average.

5 ago 2026, 19:36 UTC

Axsome Therapeutics Inc shares are lower, pulling back from earlier session highs. The stock remains significantly below its 20-day moving average.

4 ago 2026, 23:36 UTC

Axsome Therapeutics Inc shares are trading higher in after-market hours. Broader market dynamics may be influencing sentiment amid record highs in stock markets.

3 ago 2026, 22:16 UTC

Axsome Therapeutics Inc shares are higher in after-market hours, despite no specific news. The stock showed unusual activity amid broader market dynamics.

31 jul 2026, 22:01 UTC

Axsome Therapeutics Inc shares are higher in after-market trading, reflecting strong interest despite no specific news. The stock remains below its 20-day moving average.

30 jul 2026, 19:28 UTC

Axsome Therapeutics Inc is rising during Thursday's session, reversing four consecutive lower closes. The stock remains below its 20-day moving average.

29 jul 2026, 22:01 UTC

Axsome Therapeutics Inc shares are lower in after-market trading, closing below their 20-day moving average amid broader market caution and geopolitical tensions.

28 jul 2026, 19:51 UTC

Axsome Therapeutics Inc shares are lower today, breaking a trend of higher daily closes amid broader market declines, particularly in Asian markets.

27 jul 2026, 20:14 UTC

Axsome Therapeutics Inc shares are lower in after-market hours, continuing a three-session trend. No specific news was identified to explain the movement.

Comparación entre iguales

Cambio de precio

Axsome Therapeutics Inc previsión

Precio Objetivo

By TipRanks

40.8% repunte

Estimación a 12 Meses

Media 291 USD  40.8%

Máximo 380 USD

Mínimo 251 USD

De acuerdo con 13 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Axsome Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

13 ratings

12

Comprar

1

Mantener

0

Vender

Sentimiento

By Acuity

131 / 339 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Axsome Therapeutics Inc

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
help-icon Live chat